These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 16417165)
1. Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer. Cucević B; Samarzija M; Baricević D; Jakopović M; Redzepi G; Samija M Coll Antropol; 2005 Dec; 29(2):583-8. PubMed ID: 16417165 [TBL] [Abstract][Full Text] [Related]
2. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group. Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757 [TBL] [Abstract][Full Text] [Related]
3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. Crinò L; Scagliotti GV; Ricci S; De Marinis F; Rinaldi M; Gridelli C; Ceribelli A; Bianco R; Marangolo M; Di Costanzo F; Sassi M; Barni S; Ravaioli A; Adamo V; Portalone L; Cruciani G; Masotti A; Ferrara G; Gozzelino F; Tonato M J Clin Oncol; 1999 Nov; 17(11):3522-30. PubMed ID: 10550150 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369 [TBL] [Abstract][Full Text] [Related]
6. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259 [TBL] [Abstract][Full Text] [Related]
7. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679 [TBL] [Abstract][Full Text] [Related]
8. Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer. Tonato M; Crinó L; Mosconi AM Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-31-S8-35. PubMed ID: 9207314 [TBL] [Abstract][Full Text] [Related]
9. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Brodowicz T; Krzakowski M; Zwitter M; Tzekova V; Ramlau R; Ghilezan N; Ciuleanu T; Cucevic B; Gyurkovits K; Ulsperger E; Jassem J; Grgic M; Saip P; Szilasi M; Wiltschke C; Wagnerova M; Oskina N; Soldatenkova V; Zielinski C; Wenczl M; Lung Cancer; 2006 May; 52(2):155-63. PubMed ID: 16569462 [TBL] [Abstract][Full Text] [Related]
10. A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer. Goksel T; Hatipoglu ON; Ozturk C; Gorguner M; Kiyik M; Yilmaz U; Guzelant A; Tasbakan S; Tabakoglu E; Firat H; Tutar U; Cikrikicioglu S; Akkoclu A; Soyer S; Cakir E; Itil O; Sanal S Respirology; 2005 Sep; 10(4):456-63. PubMed ID: 16135168 [TBL] [Abstract][Full Text] [Related]
11. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma. Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565 [TBL] [Abstract][Full Text] [Related]
12. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. Manegold C; Drings P; von Pawel J; Ricci S; Dornoff W; van Walree N; ten Bokkel Huinink W; Chemaissani A; Stahel P; Bergman B; Wagenius G; Sederholm C; Mattson K; Liippo K; Kellokumpu-Lehtinen P Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-13-S8-17. PubMed ID: 9207310 [TBL] [Abstract][Full Text] [Related]
13. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. Cardenal F; López-Cabrerizo MP; Antón A; Alberola V; Massuti B; Carrato A; Barneto I; Lomas M; García M; Lianes P; Montalar J; Vadell C; González-Larriba JL; Nguyen B; Artal A; Rosell R J Clin Oncol; 1999 Jan; 17(1):12-8. PubMed ID: 10458212 [TBL] [Abstract][Full Text] [Related]
14. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis. Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698 [TBL] [Abstract][Full Text] [Related]
15. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Manegold C; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen P; Liippo K; Mattson K; van Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; van Walree N; ten Bokkel-Huinink W Ann Oncol; 1997 Jun; 8(6):525-9. PubMed ID: 9261520 [TBL] [Abstract][Full Text] [Related]
16. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer. Han JY; Lee DH; Song JE; Lee SY; Kim HY; Kim HT; Lee JS Cancer; 2008 Jul; 113(2):388-95. PubMed ID: 18484595 [TBL] [Abstract][Full Text] [Related]
18. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472 [TBL] [Abstract][Full Text] [Related]
19. Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV. Umihanic S; Umihanic S; Jamakosmanovic S; Brkic S; Osmic M; Dedic S; Ramic N Med Arch; 2014; 68(2):83-5. PubMed ID: 24937927 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Morabito A; Gebbia V; Di Maio M; Cinieri S; Viganò MG; Bianco R; Barbera S; Cavanna L; De Marinis F; Montesarchio V; Costanzo R; Sandomenico C; Montanino A; Mancuso G; Russo P; Nacci A; Giordano P; Daniele G; Piccirillo MC; Rocco G; Gridelli C; Gallo C; Perrone F Lung Cancer; 2013 Jul; 81(1):77-83. PubMed ID: 23643177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]